<DOC>
	<DOCNO>NCT00621725</DOCNO>
	<brief_summary>To determine patient advanced cancer various degree hepatic impairment metabolise Cediranib .</brief_summary>
	<brief_title>Phase 1 PK Study Cediranib Single Multiple Doses Hepatically Impaired Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Written inform consent Advanced solid tumour ( prostate cancer ) standard therapy exists WHO performance status 02 Bilirubin level within target range Unstable brain/meningeal metastasis Inadequate bone marrow reserve Biochemistry/haematology result outside required range History significant GI impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>